1. Home
  2. HITI vs MOLN Comparison

HITI vs MOLN Comparison

Compare HITI & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo High Tide Inc.

HITI

High Tide Inc.

HOLD

Current Price

$2.53

Market Cap

220.6M

Sector

N/A

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

HOLD

Current Price

$4.18

Market Cap

170.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
HITI
MOLN
Founded
2009
2004
Country
Canada
Switzerland
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
220.6M
170.5M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
HITI
MOLN
Price
$2.53
$4.18
Analyst Decision
Strong Buy
Buy
Analyst Count
2
2
Target Price
$6.13
$8.38
AVG Volume (30 Days)
481.2K
1.2K
Earning Date
06-15-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$23.73
N/A
Revenue Next Year
$12.80
$374.07
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.02
$3.53
52 Week High
$4.06
$5.36

Technical Indicators

Market Signals
Indicator
HITI
MOLN
Relative Strength Index (RSI) 58.64 48.08
Support Level $2.35 $4.13
Resistance Level $2.60 $4.19
Average True Range (ATR) 0.08 0.07
MACD 0.00 -0.03
Stochastic Oscillator 49.12 18.33

Price Performance

Historical Comparison
HITI
MOLN

About HITI High Tide Inc.

High Tide Inc is a downstream-focused retailer of cannabis products, distributor, and seller of smoking accessories and cannabis lifestyle products. It is a vertically integrated company in the Canadian cannabis market with various brands in its portfolio such as Canna Cabana, Fastendr, Queen of Bud, Grasscity, Daily High Club, and others. The company's reportable operating segments are: Bricks and mortar, which generates maximum revenue, and E-commerce. Geographically, it derives maximum revenue from its business in Canada, followed by the United States of America, and other international markets.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

Share on Social Networks: